Daré Bioscience Supports Clinician Education on Menopause Care After Breast Cancer

Key Points

• Daré Bioscience is the premier sponsor of a clinician education program focused on managing menopause after breast cancer.
• The October 20 event in San Diego will cover hormonal and nonhormonal approaches, sexual health and quality of life.
• The sponsorship aligns with Daré’s research into nonhormonal treatments, including its investigational Sildenafil Cream, 3.6%.
• Daré also plans to present Phase 1 data on the cream in postmenopausal women at The Menopause Society’s annual meeting.
• The announcement does not report new study results or establish the cream’s suitability for breast cancer survivors.

Daré Bioscience (NASDAQ: DARE) is sponsoring “Managing Menopause After Breast Cancer,” a continuing medical education program designed to help clinicians address the needs of women whose cancer history may complicate menopause and sexual health care.

Presented by HERmedicine and the OncoMenopause Consortium, the program takes place October 20, 2026, in San Diego, alongside the opening of The Menopause Society’s annual meeting.

Program Examines Menopause Treatment Options After Breast Cancer

A history of breast cancer—particularly hormone-sensitive cancer—can make treatment decisions more complex. The program will examine hormonal and nonhormonal approaches, sexual health concerns and the effects of menopausal symptoms on quality of life.

The event will be led by Dr. Lisa Larkin, founder and executive director of HERmedicine and the OncoMenopause Consortium, and Dr. Maryam Lustberg, director of the Yale Breast Center.

Daré CEO Sabrina Martucci Johnson said the sponsorship reflects the company’s commitment to ensuring that women’s sexual health and quality of life are recognized as essential parts of healthcare.

Sponsorship Aligns With Daré’s Nonhormonal Sexual Health Research

The educational initiative aligns with Daré’s development of nonhormonal approaches to women’s health, including its investigational Sildenafil Cream, 3.6%.

The cream acts through a mechanism involving blood flow, which the company is studying for its potential relevance to female sexual function. The announcement does not establish that it is safe or effective for breast cancer survivors.

Daré emphasized that the suitability of any treatment must be evaluated according to each woman’s medical history, symptoms and clinical circumstances.

Daré Plans Phase 1 Poster Presentation in Postmenopausal Women

Daré will also participate in The Menopause Society’s annual meeting, held October 20–24. The company plans to present a scientific poster featuring Phase 1 study data on Sildenafil Cream, 3.6% in postmenopausal women.

The announcement does not include results from that presentation or indicate that the study specifically evaluated breast cancer survivors.

Investor Takeaway: Education Sponsorship and Upcoming Data, Not a Regulatory Milestone

For DARE investors, the announcement highlights clinician engagement and an upcoming research presentation related to the company’s sexual health development program.

It does not report a regulatory approval or new clinical findings. The planned poster is the next opportunity identified in the announcement to review data on the investigational cream.